{"id":"vasopressin","_fda":{"id":"2d123e0c-8440-410e-b3f2-c30769ad72b6","set_id":"04e0c406-6b49-4c0b-abc5-9a1a75532485","openfda":{"nui":["M0022562","N0000009908","N0000175360"],"upc":["0363323930004"],"unii":["Y4907O6MFD"],"route":["INTRAVENOUS"],"rxcui":["2103182"],"spl_id":["2d123e0c-8440-410e-b3f2-c30769ad72b6"],"brand_name":["VASOPRESSIN"],"spl_set_id":["04e0c406-6b49-4c0b-abc5-9a1a75532485"],"package_ndc":["63323-930-00","63323-930-01"],"product_ndc":["63323-930"],"generic_name":["VASOPRESSIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Vasopressins [CS]"],"pharm_class_pe":["Vasoconstriction [PE]","Decreased Diuresis [PE]"],"substance_name":["VASOPRESSIN"],"manufacturer_name":["Fresenius Kabi USA, LLC"],"application_number":["ANDA213206"],"is_original_packager":[true]},"version":"9","pregnancy":["8.1 Pregnancy Risk Summary There are no available data on Vasopressin injection use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted. Clinical Considerations Dose adjustments during pregnancy and the postpartum period: Because of increased clearance of vasopressin in the second and third trimester, the dose of Vasopressin injection may need to be increased [see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )]. Maternal adverse reactions: Vasopressin injection may produce tonic uterine contractions that could threaten the continuation of pregnancy."],"overdosage":["10 OVERDOSAGE Overdosage with Vasopressin injection can be expected to manifest as consequences of vasoconstriction of various vascular beds (peripheral, mesenteric, and coronary) and as hyponatremia. In addition, overdosage may lead less commonly to ventricular tachyarrhythmias (including Torsade de Pointes), rhabdomyolysis, and nonspecific gastrointestinal symptoms. Direct effects will resolve within minutes of withdrawal of treatment."],"description":["11 DESCRIPTION Vasopressin is a polypeptide hormone. Vasopressin injection is a sterile, aqueous solution of synthetic arginine vasopressin for intravenous administration. The 1 mL solution contains vasopressin 20 units/mL, 1.36 mg sodium acetate buffer and Water for Injection, USP. Sodium hydroxide and hydrochloric acid are included to adjust to a pH of 3.8. The chemical name of vasopressin is Cyclo (1-6) L-Cysteinyl-L-Tyrosyl-L-Phenylalanyl-L-Glutaminyl- L-Asparaginyl-L-Cysteinyl-L-Prolyl-L-Arginyl-L-Glycinamide. It is a white to off-white amorphous powder, freely soluble in water. The structural formula is: vasop-struc-01.jpg"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Vasopressin injection, USP is a clear, practically colorless solution for intravenous administration available as: Product Code Unit of Sale Strength Unit of Use 930101 NDC 63323-930-01 A tray of 25 Single Dose Vials 20 Units per 1 mL NDC 63323-930-00 1 mL Single Dose Vial Store between 2°C and 8°C (36°F and 46°F). Do not freeze. Vials may be held up to 12 months upon removal from refrigeration to room temperature storage conditions (20°C to 25°C [68°F to 77°F], [see USP Controlled Room Temperature]), anytime within the labeled shelf life. Once removed from refrigeration, unopened vial should be marked to indicate the revised 12 month expiration date. If the manufacturer's original expiration date is shorter than the revised expiration date, then the shorter date must be used. Do not use Vasopressin injection beyond the manufacturer's expiration date stamped on the vial. The storage conditions and expiration periods are summarized in the following table. Unopened Refrigerated 2°C to 8°C (36°F to 46°F) Unopened Room Temperature 20°C to 25°C (68°F to 77°F) Do not store above 25°C (77°F) 1 mL Vial Until manufacturer expiration date 12 months or until manufacturer expiration date, whichever is earlier 451491A Figure"],"geriatric_use":["8.5 Geriatric Use Clinical studies of vasopressin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see Warnings and Precautions ( 5 ), Adverse Reactions ( 6 ), and Clinical Pharmacology ( 12.3 )] ."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness of Vasopressin injection in pediatric patients with vasodilatory shock have not been established."],"effective_time":"20250215","clinical_studies":["14 CLINICAL STUDIES Increases in systolic and mean blood pressure following administration of vasopressin were observed in 7 studies in septic shock and 8 in post-cardiotomy vasodilatory shock."],"pharmacodynamics":["12.2 Pharmacodynamics At therapeutic doses exogenous vasopressin elicits a vasoconstrictive effect in most vascular beds including the splanchnic, renal and cutaneous circulation. In addition, vasopressin at pressor doses triggers contractions of smooth muscles in the gastrointestinal tract mediated by muscular V 1 -receptors and release of prolactin and ACTH via V 3 receptors. At lower concentrations typical for the antidiuretic hormone vasopressin inhibits water diuresis via renal V 2 receptors. In addition, vasopressin has been demonstrated to cause vasodilation in numerous vascular beds that are mediated by V 2 , V 3 , oxytocin and purinergic P2 receptors. In patients with vasodilatory shock vasopressin in therapeutic doses increases systemic vascular resistance and mean arterial blood pressure and reduces the dose requirements for norepinephrine. Vasopressin tends to decrease heart rate and cardiac output. The pressor effect is proportional to the infusion rate of exogenous vasopressin. The pressor effect reaches its peak within 15 minutes. After stopping the infusion the pressor effect fades within 20 minutes. There is no evidence for tachyphylaxis or tolerance to the pressor effect of vasopressin in patients."],"pharmacokinetics":["12.3 Pharmacokinetics Vasopressin plasma concentrations increase linearly with increasing infusion rates from 10 to 200 μU/kg/min. Steady state plasma concentrations are achieved after 30 minutes of continuous intravenous infusion. Distribution Vasopressin does not appear to bind plasma protein. The volume of distribution is 140 mL/kg. Elimination At infusion rates used in vasodilatory shock (0.01 to 0.1 units/minute), the clearance of vasopressin is 9 to 25 mL/min/kg in patients with vasodilatory shock. The apparent t 1/2 of vasopressin at these levels is ≤ 10 minutes. Metabolism Serine protease, carboxipeptidase and disulfide oxido-reductase cleave vasopressin at sites relevant for the pharmacological activity of the hormone. Thus, the generated metabolites are not expected to retain important pharmacological activity. Excretion Vasopressin is predominantly metabolized and only about 6% of the dose is excreted unchanged into urine. Specific Populations Pregnancy: Because of a spillover into blood of placental vasopressinase, the clearance of exogenous and endogenous vasopressin increases gradually over the course of a pregnancy. During the first trimester of pregnancy, the clearance is only slightly increased. However, by the third trimester the clearance of vasopressin is increased about 4-fold and at term up to 5-fold. After delivery, the clearance of vasopressin returns to preconception baseline within two weeks. Drug Interactions Indomethacin more than doubles the time to offset for vasopressin's effect on peripheral vascular resistance and cardiac output in healthy subjects [see Drug Interactions ( 7.2 )]. The ganglionic blocking agent tetra-ethylammonium increases the pressor effect of vasopressin by 20% in healthy subjects [see Drug Interactions ( 7.3 )]. Halothane, morphine, fentanyl, alfentanyl and sufentanyl do not impact exposure to endogenous vasopressin."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions associated with the use of vasopressin were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to estimate their frequency reliably or to establish a causal relationship to drug exposure. Bleeding/lymphatic system disorders: Hemorrhagic shock, decreased platelets, intractable bleeding Cardiac disorders: Right heart failure, atrial fibrillation, bradycardia, myocardial ischemia Gastrointestinal disorders: Mesenteric ischemia Hepatobiliary: Increased bilirubin levels Renal/urinary disorders: Acute renal insufficiency Vascular disorders: Distal limb ischemia Metabolic: Hyponatremia Skin: Ischemic lesions Postmarketing Experience Reversible diabetes insipidus [see Warnings and Precautions ( 5.2 )]. The most common adverse reactions include decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia and ischemia (coronary, mesenteric, skin, digital). ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["4 CONTRAINDICATIONS Vasopressin injection 1 mL single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-L-arginine vasopressin. • Vasopressin injection 1 mL single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-L-arginine vasopressin. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS • Pressor effects of catecholamines and Vasopressin injection are expected to be additive. ( 7.1 ) • Indomethacin may prolong effects of Vasopressin injection. ( 7.2 ) • Co-administration of ganglionic blockers or drugs causing SIADH may increase the pressor response. ( 7.3 , 7.4 ) • Co-administration of drugs causing diabetes insipidus may decrease the pressor response. ( 7.5 ) 7.1 Catecholamines Use with catecholamines is expected to result in an additive effect on mean arterial blood pressure and other hemodynamic parameters. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed. 7.2 Indomethacin Use with indomethacin may prolong the effect of Vasopressin injection on cardiac index and systemic vascular resistance. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed [see Clinical Pharmacology ( 12.3 )]. 7.3 Ganglionic Blocking Agents Use with ganglionic blocking agents may increase the effect of Vasopressin injection on mean arterial blood pressure. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed [see Clinical Pharmacology ( 12.3 )]. 7.4 Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasopressin injection. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed. 7.5 Drugs Suspected of Causing Diabetes Insipidus Use with drugs suspected of causing diabetes insipidus (e.g., demeclocycline, lithium, foscarnet, clozapine) may decrease the pressor effect in addition to the antidiuretic effect of Vasopressin injection. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed."],"how_supplied_table":["
Product Code
Unit of Sale
Strength
Unit of Use
930101
NDC 63323-930-01 A tray of 25 Single Dose Vials
20 Units per 1 mL
NDC 63323-930-00 1 mL Single Dose Vial
","
Unopened Refrigerated 2°C to 8°C (36°F to 46°F)
Unopened Room Temperature 20°C to 25°C (68°F to 77°F) Do not store above 25°C (77°F)
1 mL Vial
Until manufacturer expiration date
12 months or until manufacturer expiration date, whichever is earlier
"],"mechanism_of_action":["12.1 Mechanism of Action Vasopressin causes vasoconstriction by binding to V 1 receptors on vascular smooth muscle coupled to the Gq/1 1-phospholipase C-phosphatidyl-inositol-triphosphate pathway, resulting in the release of intracellular calcium. In addition, vasopressin stimulates antidiuresis via stimulation of V 2 receptors which are coupled to adenyl cyclase."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Vasopressin causes vasoconstriction by binding to V 1 receptors on vascular smooth muscle coupled to the Gq/1 1-phospholipase C-phosphatidyl-inositol-triphosphate pathway, resulting in the release of intracellular calcium. In addition, vasopressin stimulates antidiuresis via stimulation of V 2 receptors which are coupled to adenyl cyclase. 12.2 Pharmacodynamics At therapeutic doses exogenous vasopressin elicits a vasoconstrictive effect in most vascular beds including the splanchnic, renal and cutaneous circulation. In addition, vasopressin at pressor doses triggers contractions of smooth muscles in the gastrointestinal tract mediated by muscular V 1 -receptors and release of prolactin and ACTH via V 3 receptors. At lower concentrations typical for the antidiuretic hormone vasopressin inhibits water diuresis via renal V 2 receptors. In addition, vasopressin has been demonstrated to cause vasodilation in numerous vascular beds that are mediated by V 2 , V 3 , oxytocin and purinergic P2 receptors. In patients with vasodilatory shock vasopressin in therapeutic doses increases systemic vascular resistance and mean arterial blood pressure and reduces the dose requirements for norepinephrine. Vasopressin tends to decrease heart rate and cardiac output. The pressor effect is proportional to the infusion rate of exogenous vasopressin. The pressor effect reaches its peak within 15 minutes. After stopping the infusion the pressor effect fades within 20 minutes. There is no evidence for tachyphylaxis or tolerance to the pressor effect of vasopressin in patients. 12.3 Pharmacokinetics Vasopressin plasma concentrations increase linearly with increasing infusion rates from 10 to 200 μU/kg/min. Steady state plasma concentrations are achieved after 30 minutes of continuous intravenous infusion. Distribution Vasopressin does not appear to bind plasma protein. The volume of distribution is 140 mL/kg. Elimination At infusion rates used in vasodilatory shock (0.01 to 0.1 units/minute), the clearance of vasopressin is 9 to 25 mL/min/kg in patients with vasodilatory shock. The apparent t 1/2 of vasopressin at these levels is ≤ 10 minutes. Metabolism Serine protease, carboxipeptidase and disulfide oxido-reductase cleave vasopressin at sites relevant for the pharmacological activity of the hormone. Thus, the generated metabolites are not expected to retain important pharmacological activity. Excretion Vasopressin is predominantly metabolized and only about 6% of the dose is excreted unchanged into urine. Specific Populations Pregnancy: Because of a spillover into blood of placental vasopressinase, the clearance of exogenous and endogenous vasopressin increases gradually over the course of a pregnancy. During the first trimester of pregnancy, the clearance is only slightly increased. However, by the third trimester the clearance of vasopressin is increased about 4-fold and at term up to 5-fold. After delivery, the clearance of vasopressin returns to preconception baseline within two weeks. Drug Interactions Indomethacin more than doubles the time to offset for vasopressin's effect on peripheral vascular resistance and cardiac output in healthy subjects [see Drug Interactions ( 7.2 )]. The ganglionic blocking agent tetra-ethylammonium increases the pressor effect of vasopressin by 20% in healthy subjects [see Drug Interactions ( 7.3 )]. Halothane, morphine, fentanyl, alfentanyl and sufentanyl do not impact exposure to endogenous vasopressin."],"indications_and_usage":["1 INDICATIONS AND USAGE Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. • Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Can worsen cardiac function. ( 5.1 ) • Reversible diabetes insipidus ( 5.2 ) 5.1 Worsening Cardiac Function A decrease in cardiac index may be observed with the use of vasopressin. 5.2 Reversible Diabetes Insipidus Patients may experience reversible diabetes insipidus, manifested by the development of polyuria, a dilute urine, and hypernatremia, after cessation of treatment with vasopressin. Monitor serum electrolytes, fluid status and urine output after vasopressin discontinuation. Some patients may require readministration of vasopressin or administration of desmopressin to correct fluid and electrolyte shifts."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No formal carcinogenicity or fertility studies with vasopressin have been conducted in animals. Vasopressin was found to be negative in the in vitro bacterial mutagenicity (Ames) test and the in vitro Chinese hamster ovary (CHO) cell chromosome aberration test. In mice, vasopressin has been reported to have an effect on function and fertilizing ability of spermatozoa. 13.2 Animal Toxicology and/or Pharmacology No toxicology studies were conducted with vasopressin."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • Dilute 20 units/mL single dose vial contents with normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) to either 0.1 units/mL or 1 unit/mL for intravenous administration. Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration. ( 2.1 ) • Post-cardiotomy shock: 0.03 to 0.1 units/minute ( 2.2 ) • Septic shock: 0.01 to 0.07 units/minute ( 2.2 ) 2.1 Preparation of Solution Inspect parenteral drug products for particulate matter and discoloration prior to use, whenever solution and container permit. Vasopressin Injection Solution for Dilution, 20 units/mL Dilute Vasopressin injection in normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) prior to use for intravenous administration. Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration. Table 1 Preparation of diluted solutions Fluid restriction? Final concentration Mix Vasopressin injection Diluent No 0.1 units/mL 2.5 mL (50 units) 500 mL Yes 1 unit/mL 5 mL (100 units) 100 mL 2.2 Administration In general, titrate to the lowest dose compatible with a clinically acceptable response. The recommended starting dose is: Post-cardiotomy shock: 0.03 units/minute Septic Shock: 0.01 units/minute Titrate up by 0.005 units/minute at 10- to 15-minute intervals until the target blood pressure is reached. There are limited data for doses above 0.1 units/minute for postcardiotomy shock and 0.07 units/minute for septic shock. Adverse reactions are expected to increase with higher doses. After target blood pressure has been maintained for 8 hours without the use of catecholamines, taper vasopressin injection by 0.005 units/minute every hour as tolerated to maintain target blood pressure."],"spl_product_data_elements":["VASOPRESSIN VASOPRESSIN VASOPRESSIN VASOPRESSIN SODIUM ACETATE SODIUM HYDROXIDE HYDROCHLORIC ACID WATER"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Vasopressin injection, USP is a clear, practically colorless solution available as 20 units/mL in a single dose vial. To be used after dilution. • Injection: 20 units/mL in a single dose vial. To be used after dilution. ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS • Pregnancy: May induce uterine contractions. ( 8.1 ) • Pediatric Use: Safety and effectiveness have not been established. ( 8.4 ) • Geriatric Use: No safety issues have been identified in older patients. ( 8.5 ) 8.1 Pregnancy Risk Summary There are no available data on Vasopressin injection use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted. Clinical Considerations Dose adjustments during pregnancy and the postpartum period: Because of increased clearance of vasopressin in the second and third trimester, the dose of Vasopressin injection may need to be increased [see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )]. Maternal adverse reactions: Vasopressin injection may produce tonic uterine contractions that could threaten the continuation of pregnancy. 8.2 Lactation There are no data on the presence of vasopressin injection in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. 8.4 Pediatric Use Safety and effectiveness of Vasopressin injection in pediatric patients with vasodilatory shock have not been established. 8.5 Geriatric Use Clinical studies of vasopressin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see Warnings and Precautions ( 5 ), Adverse Reactions ( 6 ), and Clinical Pharmacology ( 12.3 )] ."],"dosage_and_administration_table":["
Table 1 Preparation of diluted solutions
Fluid restriction?
Final concentration
Mix
Vasopressin injection
Diluent
No
0.1 units/mL
2.5 mL (50 units)
500 mL
Yes
1 unit/mL
5 mL (100 units)
100 mL
"],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology No toxicology studies were conducted with vasopressin."],"package_label_principal_display_panel":["PACKAGE LABEL- PRINCIPAL DISPLAY PANEL- VASOPRESSIN INJECTION 20 Unit Tray Label NDC 63323-930-01 Rx Only Vasopressin Injection, USP 20 Units per mL For Intravenous Infusion Must be diluted prior to use Store between 2°C and 8°C (36°F and 46°F). Vials may be held at 20°C to 25°C (68°F to 77°F) for up to 12 months. Do not store above 25°C (77°F). Avoid freezing. 25 x 1 mL Single Dose Vials vasop-label-01.jpg","PACKAGE LABEL- PRINCIPAL DISPLAY PANEL- VASOPRESSIN INJECTION 20 Unit Vial Label NDC 63323-930-00 930101 Vasopressin Injection, USP 20 Units per mL For Intravenous Infusion Must be diluted prior to use. Usual Dosage: See insert. Store between 2°C and 8°C (36°F and 46°F). Do not store above 25°C (77°F) 1 mL Single Dose Vial Rx Only vasop-label-02.jpg"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No formal carcinogenicity or fertility studies with vasopressin have been conducted in animals. Vasopressin was found to be negative in the in vitro bacterial mutagenicity (Ames) test and the in vitro Chinese hamster ovary (CHO) cell chromosome aberration test. In mice, vasopressin has been reported to have an effect on function and fertilizing ability of spermatozoa."]},"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"1262 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"512 reports"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"486 reports"},{"date":"","signal":"CARDIOGENIC SHOCK","source":"FDA FAERS","actionTaken":"389 reports"},{"date":"","signal":"SEPSIS","source":"FDA FAERS","actionTaken":"380 reports"},{"date":"","signal":"MULTIPLE ORGAN DYSFUNCTION SYNDROME","source":"FDA FAERS","actionTaken":"375 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"359 reports"},{"date":"","signal":"TOXICITY TO VARIOUS AGENTS","source":"FDA FAERS","actionTaken":"317 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"308 reports"},{"date":"","signal":"STRESS","source":"FDA FAERS","actionTaken":"289 reports"}],"commonSideEffects":[{"effect":"Decreased cardiac output","drugRate":"","severity":"common","organSystem":""},{"effect":"Bradycardia","drugRate":"","severity":"common","organSystem":""},{"effect":"Tachyarrhythmias","drugRate":"","severity":"common","organSystem":""},{"effect":"Hyponatremia","drugRate":"","severity":"common","organSystem":""},{"effect":"Ischemia (coronary)","drugRate":"","severity":"common","organSystem":""},{"effect":"Ischemia (mesenteric)","drugRate":"","severity":"common","organSystem":""},{"effect":"Ischemia (skin)","drugRate":"","severity":"common","organSystem":""},{"effect":"Ischemia (digital)","drugRate":"","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Hemorrhagic shock","drugRate":"","severity":"serious"},{"effect":"Myocardial ischemia","drugRate":"","severity":"serious"},{"effect":"Right heart failure","drugRate":"","severity":"serious"},{"effect":"Mesenteric ischemia","drugRate":"","severity":"serious"},{"effect":"Acute renal insufficiency","drugRate":"","severity":"serious"},{"effect":"Distal limb ischemia","drugRate":"","severity":"serious"},{"effect":"Intractable bleeding","drugRate":"","severity":"serious"},{"effect":"Atrial fibrillation","drugRate":"","severity":"serious"},{"effect":"Ischemic lesions","drugRate":"","severity":"serious"},{"effect":"Reversible diabetes insipidus","drugRate":"","severity":"serious"}]},"_chembl":{"chemblId":"CHEMBL1201528","moleculeType":"Protein"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=VASOPRESSIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:06:09.782112+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T04:06:37.404555+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:06:16.831640+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T04:06:08.419595+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VASOPRESSIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:06:17.802991+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:06:07.372622+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:06:32.875848+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:06:07.372679+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T04:06:19.356354+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Vasopressin V1b receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:06:18.426102+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201528/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:06:18.310959+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA213206","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:06:07.372690+00:00"}},"_dailymed":{"setId":"b1147beb-743e-4c62-8927-91192447f8b8","title":"VASOSTRICT (VASOPRESSIN) INJECTION [PAR HEALTH USA, LLC]"},"aiSummary":"Vasopressin is a marketed drug primarily indicated for the treatment of vasodilatory shock. Its key strength lies in its established mechanism and indication, providing a clear therapeutic option in critical care settings. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.","_scrapedAt":"2026-03-27T23:39:23.523Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T04:06:37.404979+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"vasopressin-vasodilatory-shock-treatment","name":"Vasodilatory Shock Treatment","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines","diagnosticRequired":null,"brandNameForIndication":""}]},"trialDetails":[{"nctId":"NCT04569591","phase":"NA","title":"DDAVP for Pituitary Adenoma","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2026-03-09","conditions":"Cushing's Disease, Pituitary Adenoma","enrollment":22},{"nctId":"NCT06337838","phase":"PHASE3","title":"Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial","status":"RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2025-06-09","conditions":"Chronic Kidney Diseases, Acute Kidney Injury, Bleeding","enrollment":100},{"nctId":"NCT07292753","phase":"NA","title":"Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-12-15","conditions":"Nocturnal Enuresis, Vitamin D Deficiency","enrollment":90},{"nctId":"NCT05958342","phase":"PHASE2","title":"CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial","status":"RECRUITING","sponsor":"Jason Sperry","startDate":"2024-06-30","conditions":"Trauma, Hemorrhage","enrollment":1050},{"nctId":"NCT06709573","phase":"PHASE4","title":"Early Versus Late Adjunctive Vasopressin in Septic Shock","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2025-04-29","conditions":"Sepsis, Septic Shock","enrollment":300},{"nctId":"NCT07460908","phase":"NA","title":"Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome","status":"COMPLETED","sponsor":"Lahore General Hospital","startDate":"2025-05-01","conditions":"Hepatorenal Syndrome","enrollment":60},{"nctId":"NCT07446933","phase":"PHASE2","title":"Vasopressin vs. Uterine Artery Clamping for Laparoscopic Cesarean Scar Niche Repair","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2024-03-20","conditions":"Cesarean Section Complications","enrollment":30},{"nctId":"NCT07438925","phase":"","title":"Copeptin Concentration Measured in Plasma Samples and Intradialytic Blood Pressure Variation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-12-22","conditions":"Hemodialysis","enrollment":71},{"nctId":"NCT07423156","phase":"PHASE3","title":"Tranexamic Acid vs Vasopressin in Placenta Previa Trial","status":"NOT_YET_RECRUITING","sponsor":"Allama Iqbal Medical College","startDate":"2026-03-01","conditions":"Placenta Previa","enrollment":58},{"nctId":"NCT06426407","phase":"","title":"Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2025-10-01","conditions":"Shock, Septic","enrollment":2},{"nctId":"NCT07276152","phase":"NA","title":"Plasma Oxytocin Changes in Response to Music Modified by Sonic Augmentation Technology","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2026-01-09","conditions":"Sonic Augmentation Technology","enrollment":22},{"nctId":"NCT06344442","phase":"PHASE3","title":"Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-04-16","conditions":"Acute Kidney Injury Post Liver Transplantation","enrollment":304},{"nctId":"NCT05824767","phase":"PHASE4","title":"Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2023-04-17","conditions":"Septic Shock, Vasodilatory Shock","enrollment":40},{"nctId":"NCT06464510","phase":"PHASE3","title":"Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis","status":"RECRUITING","sponsor":"Hospital do Coracao","startDate":"2024-11-21","conditions":"Septic Shock","enrollment":2800},{"nctId":"NCT05738148","phase":"PHASE1","title":"Vasopressin vs. Epinephrine During Neonatal Cardiopulmonary Resuscitation","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2023-11-27","conditions":"Cardiac Arrest Neonatal","enrollment":20},{"nctId":"NCT05190744","phase":"PHASE2","title":"Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-09-01","conditions":"Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus, Acquired Nephrogenic Diabetes Insipidus","enrollment":36},{"nctId":"NCT07063680","phase":"PHASE3","title":"Efficacy of Early Argipressin in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2026-01","conditions":"Patients With Norepinephrine-refractory Vasoplegic Shock","enrollment":390},{"nctId":"NCT06771128","phase":"NA","title":"Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis","status":"COMPLETED","sponsor":"Menoufia University","startDate":"2024-11-01","conditions":"Nocturnal Enuresis in Children, Desmopressin, Monosymptomatic Nocturnal Enuresis","enrollment":398},{"nctId":"NCT06930300","phase":"NA","title":"Vasopressin in the Elderly: Physiological Changes in Neuroendocrine Function and Urinary Secretion in Healthy Aging","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-04-30","conditions":"Healthy Ageing","enrollment":32},{"nctId":"NCT02118467","phase":"PHASE4","title":"Vasoactive Drugs in Intensive Care Unit","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2014-05-15","conditions":"Shock","enrollment":836},{"nctId":"NCT07328529","phase":"PHASE2","title":"Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Azevan Pharmaceuticals","startDate":"2026-03","conditions":"Aggressive Behavior in Fragile X Syndome","enrollment":80},{"nctId":"NCT06344143","phase":"","title":"Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2024-11-20","conditions":"Mild Autonomous Cortisol Secretion (MACS)","enrollment":20},{"nctId":"NCT06036004","phase":"PHASE2","title":"Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2024-01-08","conditions":"Central Diabetes Insipidus (cDI)","enrollment":112},{"nctId":"NCT07067866","phase":"PHASE3","title":"Weaning Approaches for Vasopressin in Sepsis","status":"RECRUITING","sponsor":"Hospital Nossa Senhora da Conceicao","startDate":"2025-10-01","conditions":"Septic Shock","enrollment":82},{"nctId":"NCT07304466","phase":"NA","title":"Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Istanbul Medipol University Hospital","startDate":"2025-12-29","conditions":"Liver Transplantation, Portal Hypertension","enrollment":50},{"nctId":"NCT05568160","phase":"PHASE3","title":"Evaluation of the Superiority of VAsopressin Versus NOradrenaline in the Management of Patients at Risk of Kidney Failure Undergoing Cardiac Surgery With Extracorporeal Circulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2023-01-02","conditions":"Scheduled Cardiac Surgery With Extracorporeal Circulation, Vasoplegic Syndrome","enrollment":840},{"nctId":"NCT07286643","phase":"NA","title":"Echocardiography-guided Cirrhosis and Liver Failure-Intensive Care Protocol Sepsis","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2026-01-01","conditions":"Cirrhosis, Liver, Cirrhotic Cardiomyopathy, Septic Shock","enrollment":140},{"nctId":"NCT07255378","phase":"","title":"Use of Vassopresin in Septic Shock Prospective Multicenter Observational Study With Medication","status":"RECRUITING","sponsor":"Jamil Cedeño Mora","startDate":"2025-10-01","conditions":"Septic Shock","enrollment":1200},{"nctId":"NCT06542198","phase":"NA","title":"Mannitol-induced Release of Copeptin in Healthy Adults and Patients With Polyuria-Polydipsia Syndrome (MARS Study)","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2024-09-10","conditions":"Polyuria-polydipsia Syndrome, Arginine Vasopressin Deficiency, Primary Polydipsia","enrollment":42},{"nctId":"NCT06161766","phase":"","title":"Terlipressin in Combined Hepatorenal Syndrome in Patients With Signs of Chronic Renal Disease","status":"COMPLETED","sponsor":"University Hospital Freiburg","startDate":"2024-03-03","conditions":"Liver Cirrhosis, Hepato-Renal Syndrome, Chronic Kidney Diseases","enrollment":490},{"nctId":"NCT03422848","phase":"NA","title":"Hydration to Optimize Metabolism","status":"COMPLETED","sponsor":"Region Skane","startDate":"2018-04-24","conditions":"Glucose, High Blood","enrollment":797},{"nctId":"NCT07252401","phase":"NA","title":"Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Gastrointestinal Bleeding and Acute Kidney Injury","status":"NOT_YET_RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-12-25","conditions":"Liver Cirrhosis","enrollment":64},{"nctId":"NCT06203847","phase":"NA","title":"The Effect of Prehospital Combination of Epinephrine, Vasopressin, and Steroid in OHCA","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-07-16","conditions":"Cardiac Arrest, Out-Of-Hospital Cardiac Arrest, Emergency Medical Services","enrollment":1344},{"nctId":"NCT07143266","phase":"","title":"Sleep Disorders in Hypothalamic and Pituitary Damage","status":"RECRUITING","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2025-09-01","conditions":"Hypopituitarism, Sleep Wake Disorders, Hypothalamic Diseases","enrollment":60},{"nctId":"NCT05766852","phase":"NA","title":"Potential Benefits of the Somatic Psychoeducational Intervention","status":"COMPLETED","sponsor":"University of Florida","startDate":"2023-10-23","conditions":"Work Related Stress","enrollment":31},{"nctId":"NCT07102615","phase":"PHASE4","title":"Intracervical Vasopressin","status":"RECRUITING","sponsor":"Prisma Health-Upstate","startDate":"2025-10-30","conditions":"Retained Products of Conception","enrollment":50},{"nctId":"NCT03707054","phase":"NA","title":"Vasopressin in Intraabdominal Pressure Elevation","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2017-04-28","conditions":"Intracranial Pressure Increase, Abdominal Compartment Syndrome","enrollment":16},{"nctId":"NCT06635629","phase":"PHASE2","title":"Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2024-12-12","conditions":"Cushing Syndrome","enrollment":140},{"nctId":"NCT06217562","phase":"PHASE4","title":"Vasopressin for Septic Shock Pragmatic Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Intermountain Health Care, Inc.","startDate":"2024-02-01","conditions":"Septic Shock","enrollment":2050},{"nctId":"NCT06605300","phase":"NA","title":"The Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling","status":"COMPLETED","sponsor":"University of Electronic Science and Technology of China","startDate":"2024-10-02","conditions":"Healthy","enrollment":120},{"nctId":"NCT06808516","phase":"PHASE2","title":"Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-07-01","conditions":"Arginine Vasopressin Deficiency, Central Diabetes Insipidus, Oxytocin Deficiency","enrollment":42},{"nctId":"NCT07199894","phase":"PHASE3","title":"Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2024-12-01","conditions":"Nocturnal Enuresis in Children","enrollment":120},{"nctId":"NCT03204786","phase":"PHASE2, PHASE3","title":"Intranasal Vasopressin Treatment in Children With Autism","status":"COMPLETED","sponsor":"Stanford University","startDate":"2018-02-20","conditions":"Autism, Autism Spectrum Disorder, ASD","enrollment":157},{"nctId":"NCT04789148","phase":"PHASE1","title":"Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency","status":"RECRUITING","sponsor":"Elizabeth Austen Lawson","startDate":"2025-09-10","conditions":"Vasopressin Deficiency","enrollment":40},{"nctId":"NCT06361693","phase":"","title":"Descriptive Observational Study of Patient-performed Pre-oxygenation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-10-14","conditions":"Anesthesia, ASA Physical Status I, ASA Physical Status II","enrollment":110},{"nctId":"NCT04592744","phase":"PHASE4","title":"Angiotensin 2 for AKI After OLT","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, Los Angeles","startDate":"2022-04-08","conditions":"Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury","enrollment":30},{"nctId":"NCT06622187","phase":"PHASE4","title":"Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2024-08-14","conditions":"Bleeding, Transplant, Kidney, Desmopressin","enrollment":96},{"nctId":"NCT06502158","phase":"PHASE1","title":"Mifepristone vs Misoprostol","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2024-10-31","conditions":"Cervical Preparation","enrollment":94},{"nctId":"NCT07052084","phase":"PHASE3","title":"Systematic Adjunction of Vasopressine in Septic Shock","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2026-01","conditions":"Septic Shock","enrollment":120},{"nctId":"NCT03064568","phase":"PHASE4","title":"Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-10-14","conditions":"Myomectomy; Surgical Blood Loss","enrollment":18},{"nctId":"NCT06821802","phase":"NA","title":"Protein Supplementation in Hyponatremia Due to the Syndrome of Inappropriate Antidiuresis","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-04-14","conditions":"Hyponatremia, Syndrome of Inappropriate Antidiuresis","enrollment":70},{"nctId":"NCT06155812","phase":"PHASE2, PHASE3","title":"Multimodal Vasopressor Strategy in Septic Shock","status":"RECRUITING","sponsor":"University Medical Centre Maribor","startDate":"2023-12-23","conditions":"Shock, Septic","enrollment":80},{"nctId":"NCT04591990","phase":"PHASE3","title":"HYdrocortisone and VAsopressin in Post-RESuscitation Syndrome","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-05-27","conditions":"Postresuscitation Syndrome","enrollment":380},{"nctId":"NCT04682483","phase":"","title":"Cardiogenic Shock Working Group Registry","status":"RECRUITING","sponsor":"Tufts Medical Center","startDate":"2017-12-04","conditions":"Cardiogenic Shock","enrollment":5000},{"nctId":"NCT06020495","phase":"PHASE3","title":"Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-12-17","conditions":"Hyponatremia","enrollment":260},{"nctId":"NCT06676774","phase":"PHASE2","title":"Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus and Healthy Controls","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-05-16","conditions":"Arginine Vasopressin Deficiency, Diabetes Insipidus","enrollment":42},{"nctId":"NCT03446456","phase":"PHASE1, PHASE2","title":"Vasopressin and Pain Perception in the Brain","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2018-09-17","conditions":"Acute Pain","enrollment":40},{"nctId":"NCT04463394","phase":"EARLY_PHASE1","title":"The Hemodynamic Effects of Vasopressin in Patients With Fontan Physiology","status":"COMPLETED","sponsor":"Stanford University","startDate":"2020-08-12","conditions":"Hypotension, Fontan Physiology","enrollment":28},{"nctId":"NCT05467033","phase":"PHASE3","title":"Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin","status":"RECRUITING","sponsor":"Medical University of Bialystok","startDate":"2022-09-01","conditions":"Kidney Biopsy","enrollment":424},{"nctId":"NCT06953297","phase":"","title":"Vasopressin Use in Septic Shock From Türkiye","status":"COMPLETED","sponsor":"Karadeniz Technical University","startDate":"2024-01-01","conditions":"Septic Shock, Vasodilatory Shock, Critical Illness Sepsis, Severe","enrollment":146},{"nctId":"NCT06934798","phase":"PHASE4","title":"Inotropic Effects of Vasopressin Versus Noradrenaline In Patients With Vasoplegic Syndrome After Cardiac Surgery","status":"RECRUITING","sponsor":"University of Sao Paulo","startDate":"2024-04-01","conditions":"Vasoplegic Syndrome of Cardiac Surgery","enrollment":350},{"nctId":"NCT06547892","phase":"PHASE2","title":"Use of Vasopressin in Patients at High Risk of Acute Kidney Injury Admitted to the ICU","status":"RECRUITING","sponsor":"Hospital do Coracao","startDate":"2025-04-10","conditions":"Critical Illness","enrollment":60},{"nctId":"NCT06234592","phase":"NA","title":"The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock","status":"RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2024-01-05","conditions":"Septic Shock, Acute Kidney Injury","enrollment":45},{"nctId":"NCT02785224","phase":"","title":"Arterial Pressure and Stress-Dose Steroids in Cardiac Arrest.","status":"WITHDRAWN","sponsor":"University of Athens","startDate":"2025-12","conditions":"Cardiac Arrest","enrollment":""},{"nctId":"NCT04501861","phase":"PHASE3","title":"Hemodynamic Effect of Norepinephrine Versus Vasopressin on the Pulmonary Circulation in Cardiac Surgery Patients:","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2020-11-05","conditions":"Cardiac Disease","enrollment":153},{"nctId":"NCT04790175","phase":"","title":"Samsca Post-marketing General Drug Use-results Survey in Patients with Hyponatremia in SIADH","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2021-03-29","conditions":"Antidiuretic Hormone, Inappropriate Secretion","enrollment":300},{"nctId":"NCT06855758","phase":"NA","title":"Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2025-03-06","conditions":"Kidney Transplant, Delayed Graft Function, Intraoperative Hypotension","enrollment":150},{"nctId":"NCT05506319","phase":"PHASE4","title":"Hypotension in the Weaning From Vasopressor Drugs","status":"COMPLETED","sponsor":"Hospital Nossa Senhora da Conceicao","startDate":"2022-05-01","conditions":"Septic Shock","enrollment":78},{"nctId":"NCT05293041","phase":"PHASE4","title":"Argipressin's Influence on Blood Loss During Hepatic Resection","status":"COMPLETED","sponsor":"Kristina Svennerholm","startDate":"2022-03-27","conditions":"Colon Cancer Liver Metastasis, Inflammatory Response, Vasopressin Causing Adverse Effects in Therapeutic Use","enrollment":248},{"nctId":"NCT06853574","phase":"NA","title":"Ventriculo-arterial Coupling and Myocardial Work in Sepsis and Septic Shock","status":"NOT_YET_RECRUITING","sponsor":"General and Teaching Hospital Celje","startDate":"2025-02","conditions":"Sepsis, Septic Shock","enrollment":30},{"nctId":"NCT06789705","phase":"NA","title":"Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-01-27","conditions":"Central Diabetes Insipidus","enrollment":24},{"nctId":"NCT06460948","phase":"EARLY_PHASE1","title":"Identifying Oxytocin Deficiency in Adults With Pituitary Disease","status":"RECRUITING","sponsor":"Elizabeth Austen Lawson","startDate":"2024-11-13","conditions":"Arginine Vasopressin Deficiency, Oxytocin Deficiency","enrollment":32},{"nctId":"NCT06419075","phase":"PHASE4","title":"Tranexamic Acid in Vaginal Reconstructive Surgery","status":"WITHDRAWN","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2024-07-01","conditions":"Pelvic Organ Prolapse","enrollment":""},{"nctId":"NCT06256432","phase":"PHASE2","title":"Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome","status":"RECRUITING","sponsor":"Noorik Biopharmaceuticals AG","startDate":"2024-04-17","conditions":"Hepatorenal Syndrome, Liver Cirrhosis, Acute Kidney Injury","enrollment":54},{"nctId":"NCT06772584","phase":"NA","title":"Ginko Biloba Versus Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis","status":"COMPLETED","sponsor":"Menoufia University","startDate":"2024-01-01","conditions":"Enuresis, Nocturnal","enrollment":90},{"nctId":"NCT04329975","phase":"","title":"Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2020-05-19","conditions":"Nocturia Due to Nocturnal Polyuria","enrollment":1087},{"nctId":"NCT05346393","phase":"NA","title":"HRS-AKI Treatment With TIPS in Patients With Cirrhosis","status":"RECRUITING","sponsor":"Jena University Hospital","startDate":"2022-11-29","conditions":"Cirrhosis, Liver, Hepatorenal Syndrome, Acute Kidney Injury","enrollment":124},{"nctId":"NCT02975999","phase":"PHASE2, PHASE3","title":"Use of Vasopressin Following the Fontan Operation","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-12","conditions":"Pleural Effusion, Single-ventricle","enrollment":12},{"nctId":"NCT04460560","phase":"PHASE3","title":"Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-12-11","conditions":"Hepatorenal Syndrome","enrollment":50},{"nctId":"NCT05507476","phase":"NA","title":"Nasal Desmopressin Versus Topical Epinephrine in Endonasal Dacryocystorhinostomy","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2022-09-01","conditions":"Anesthesia","enrollment":52},{"nctId":"NCT06556472","phase":"NA","title":"Safety and Efficacy of Continuous Infusion of Terlipressin With Norepinephrine Versus Norepinephrine Alone in Improving Outcomes of Acute Kidney Injury in Acute on Chronic Liver Failure With Septic Shock","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2024-08-15","conditions":"Acute on Chronic Liver Failure","enrollment":126},{"nctId":"NCT04950270","phase":"","title":"Copeptin Kinetics in Critically Ill Patients With Posterior Reversible Encephalopathy Syndrome","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2022-06-18","conditions":"Posterior Reversible Encephalopathy Syndrome","enrollment":24},{"nctId":"NCT06499467","phase":"","title":"Norepinephrine Equivalent Dose of Vasopressin, Phenylephrine and Epinephrine in Septic Shock","status":"RECRUITING","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2024-07-12","conditions":"Septic Shock","enrollment":100},{"nctId":"NCT06422975","phase":"","title":"Registry of Patients in Shock Treated With Vasopressin","status":"RECRUITING","sponsor":"Hospital Universitario 12 de Octubre","startDate":"2024-07-09","conditions":"Vasopressin Causing Adverse Effects in Therapeutic Use, Shock, Vasopressor Adverse Reaction","enrollment":500},{"nctId":"NCT06498856","phase":"","title":"Saline Infusion Test in Hyponatremia","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2024-07","conditions":"Hyponatremia","enrollment":100},{"nctId":"NCT05154279","phase":"NA","title":"The Effect of Intramyometrial Injection of Terlipressin Versus Intramyometrial Injection of Carbitocin on Hemoglobin and Blood Loss During Laparoscopic Myomectomy Operations","status":"RECRUITING","sponsor":"Wael Elbanna Clinic","startDate":"2022-02-27","conditions":"Laparoscopic Myomectomy","enrollment":99},{"nctId":"NCT05242783","phase":"NA","title":"The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Using Haemostatic Tourniquets:","status":"COMPLETED","sponsor":"Wael Elbanna Clinic","startDate":"2022-02-01","conditions":"Myoma","enrollment":99},{"nctId":"NCT05170230","phase":"NA","title":"The Effect of Intracapsular Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Laparoscopic Myomectomy Operations","status":"RECRUITING","sponsor":"Wael Elbanna Clinic","startDate":"2022-02-27","conditions":"Myoma","enrollment":99},{"nctId":"NCT06471231","phase":"PHASE4","title":"Renal Outcomes in the Early Use of Vasopressin in the Treatment of Septic Shock","status":"RECRUITING","sponsor":"Azienda Usl di Bologna","startDate":"2024-05-15","conditions":"Septic Shock, Renal Function Replacement","enrollment":264},{"nctId":"NCT04420585","phase":"PHASE4","title":"Desmopressin for Bedwetting in Children With SCD","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2020-07-07","conditions":"Nocturnal Enuresis, Anemia, Sickle Cell","enrollment":8},{"nctId":"NCT04961528","phase":"PHASE3","title":"ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-03-27","conditions":"Hemoptysis","enrollment":315},{"nctId":"NCT06285006","phase":"NA","title":"Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis","status":"RECRUITING","sponsor":"Al-Azhar University","startDate":"2024-02-23","conditions":"Nocturnal Enuresis","enrollment":50},{"nctId":"NCT06376318","phase":"","title":"Shock and Acute Conditions OutcOmes Platform","status":"ACTIVE_NOT_RECRUITING","sponsor":"Saint-Louis Hospital, Paris, France","startDate":"2024-01-01","conditions":"Circulatory Shock, Sepsis, Cardiogenic Shock","enrollment":1000},{"nctId":"NCT06329063","phase":"NA","title":"Oral Vasopressin Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study","status":"RECRUITING","sponsor":"University of Electronic Science and Technology of China","startDate":"2024-03-05","conditions":"Healthy","enrollment":80},{"nctId":"NCT06329037","phase":"NA","title":"The Effects of Oral Vasopressin on Attention Control: An Eye-tracking Study","status":"RECRUITING","sponsor":"University of Electronic Science and Technology of China","startDate":"2024-03-05","conditions":"Healthy","enrollment":80},{"nctId":"NCT04602767","phase":"PHASE4","title":"Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2020-10-15","conditions":"Acute Kidney Injury","enrollment":300},{"nctId":"NCT04103034","phase":"PHASE1","title":"A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers","status":"COMPLETED","sponsor":"Band Therapeutics","startDate":"2019-10-07","conditions":"Cerebrovascular Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis), Intracranial Arteriosclerosis","enrollment":112},{"nctId":"NCT06255366","phase":"PHASE4","title":"Analysis of the Clinical Efficacy of Intravenous Application of Hemostatic Drugs in Improving the Clarity of Vision Under Endoscope, Perioperative Bleeding Volume and Anti-inflammatory Effect of Spinal Endoscopic Lumbar Fusion","status":"NOT_YET_RECRUITING","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2024-03-28","conditions":"Lumbar Spondylolisthesis, Arthrosis; Spine","enrollment":126},{"nctId":"NCT05193370","phase":"PHASE4","title":"Angiotensin II vs. Vasopressin in Septic Shock","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2022-01-03","conditions":"Septic Shock","enrollment":""},{"nctId":"NCT06302998","phase":"PHASE2","title":"Dexmedetomidine and Vasopressin in Septic Shock","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2024-06","conditions":"Sepsis, Septic Shock","enrollment":260}],"_emaApprovals":[],"_faersSignals":[{"count":1293,"reaction":"DRUG INEFFECTIVE"},{"count":534,"reaction":"HYPOTENSION"},{"count":519,"reaction":"OFF LABEL USE"},{"count":400,"reaction":"SEPSIS"},{"count":399,"reaction":"CARDIOGENIC SHOCK"},{"count":383,"reaction":"MULTIPLE ORGAN DYSFUNCTION SYNDROME"},{"count":364,"reaction":"CONDITION AGGRAVATED"},{"count":321,"reaction":"TOXICITY TO VARIOUS AGENTS"},{"count":317,"reaction":"ACUTE KIDNEY INJURY"},{"count":309,"reaction":"STRESS"}],"administration":{"route":"Intravenous"},"crossReferences":{"chemblId":"CHEMBL1201528"},"_approvalHistory":[{"date":"20220718","type":"ORIG","sponsor":"AMPHASTAR PHARMS INC","applicationNumber":"ANDA211857"},{"date":"20200803","type":"ORIG","sponsor":"AM REGENT","applicationNumber":"NDA212593"},{"date":"20220815","type":"ORIG","sponsor":"EUGIA PHARMA","applicationNumber":"ANDA214314"},{"date":"20240711","type":"ORIG","sponsor":"LONG GROVE PHARMS","applicationNumber":"NDA217766"},{"date":"20240508","type":"ORIG","sponsor":"DR REDDYS","applicationNumber":"ANDA213988"}],"publicationCount":37714,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"VASOPRESSIN","genericName":"VASOPRESSIN","companyName":"","companyId":"","modality":"Recombinant protein","firstApprovalDate":"2014","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-08-03T00:00:00.000Z","mah":"AM REGENT","brand_name_local":null,"application_number":"NDA212593"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-07-18T00:00:00.000Z","mah":"AMPHASTAR PHARMS INC","brand_name_local":null,"application_number":"ANDA211857"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-08-05T00:00:00.000Z","mah":"AMNEAL","brand_name_local":null,"application_number":"ANDA212944"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-08-15T00:00:00.000Z","mah":"EUGIA PHARMA","brand_name_local":null,"application_number":"ANDA214314"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-02-05T00:00:00.000Z","mah":"BAXTER HLTHCARE CORP","brand_name_local":null,"application_number":"NDA217569"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T04:06:37.404979+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}